Key Leaders’ Opinion on Novel Progress in Treatment of Kidney Cancer

Posted On 2020-12-10 16:21:30
Key Leaders’ Opinion on Novel Progress in Treatment of Kidney Cancer
Editors: Ninghong Song, Bin Yu, Xiao Li, Mark W. Ball

Publisher: AME Publishing Company; 1st edition (2020)
ISBN: 978-988-74593-2-3
Hardcover: 307 pages
Language: English
Available at:

This book will provide the urologist, oncologist, other clinicians, and more basic science researchers with the latest knowledge of surgical treatment, immunotherapy including immune checkpoints, stereotactic body radiation, minimally invasive treatment and latest developments of translational medicine. This book contains 77 chapters in 5 parts covering debates and difficulty in surgical treatment, precision medicine for individualized therapy, research and perspectives from fresh vision, basic research and translation medicine, molecular genetics, renal tumor immune dysfunction, and signal transduction. An acknowledged expert in that specialty wrote each of the articles, and the list of authors represents decades of experience in dealing with clinical management of RCC.
This book covers topics that over the years have been quite controversial, like lymph node dissection in RCC, nephrectomy in metastatic RCC with venous thrombus, surgical metastasectomy for RCC, acute kidney injury after partial nephrectomy, complex partial nephrectomy, use of anti-vascular and anti-endothelial growth factor targeted agents before cytoreductive surgery, active surveillance and the role of immunotherapy among many other topics.

HONORARY EDITORS

Zengjun Wang Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Gaetano Ciancio Department of Surgery and Urology, Miami Transplant Institute, University of Miami Miller School of Medicine,Jackson Memorial Hospital, Miami, FL, USA
Riccardo Autorino Division of Urology, VCU Health System, Richmond, Virginia, USA

EDITORS

Ninghong Song Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; The Affiliated Kezhou People’s Hospital of Nanjing Medical University, Kezhou, China
Bin Yu Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
Xiao Li Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
Mark W. Ball Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

ASSOCIATE EDITORS

Jie Yang Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Jianxin Xue Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Departmentof Urology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China